Biography:
Marc L. Berger, M.D. is executive vice president and senior scientist, in the life sciences group of OptumInsight (formerly known as Ingenix). A native of New York, he has held senior positions in the pharmaceutical industry including Vice President, Outcomes Research and Management at Merck & Co., Inc. from 2002 – 2007, and Vice President, Global Health Outcomes, at Eli Lilly and Company from 2007 - 2011. He obtained an M.D. degree from Johns Hopkins University School of Medicine and has held adjunct appointments as Senior Fellow at the Leonard Davis Institute at the Wharton School of the University of Pennsylvania and Professor in the Department of Health Policy and Administration at the University of North Carolina at Chapel Hill School of Public Health. He has served on the Medicare Evidence Development & Coverage Advisory Committee (MedCAC) for the Center for Medicare & Medicaid Services (CMS), the board of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the steering committee for the Agency for Health Care Research and Quality (AHRQ) Centers for Research and Education on Therapeutics (CERTs), the board of the Health Industry Forum of the Heller School for Social Policy and Management at Brandeis University and the Editorial Advisory Board of Value in Health. Currently, he is a member of the editorial advisory board of the Journal of Comparative Effectiveness, the advisory council for North America (ACNA) of the Drug Information Association (DIA) and the Green Park Collaborative on HTA/Payer Methods Guidance coordinated by the Center for Medical Technology Policy (CMTP). He also currently serves as co-chair the ISPOR Taskforce on Prospective Observational Studies for Comparative Effectiveness Research and as chair of the AMCP/NPC/ISPOR Comparative Effectiveness Collaborative IntiativeTaskforce for the Interpreting Prospective Observational Studies for Health Care Decisions. Marc has published widely in peer-reviewed journals